Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12578115 | 0.90 | FFAR1 (0.40) | KDM4ECD274ALDH1A1PDCD1FFAR1 | |
| SCHEMBL2022943 | 0.90 | CD274 (0.38) | KDM4ECD274ALDH1A1L3MBTL1PDCD1 | |
| SCHEMBL13117752 | 0.83 | FFAR1 (0.42) | KDM4ECD274ALDH1A1L3MBTL1PDCD1 | |
| SCHEMBL12577734 | 0.82 | FFAR1 (0.38) | KDM4ECD274ALDH1A1PDCD1FFAR1 | |
| SCHEMBL12578278 | 0.82 | CD274 (0.44) | KDM4ECD274PDCD1 | |
| SCHEMBL12578196 | 0.81 | FFAR1 (0.35) | KDM4EALDH1A1L3MBTL1POLBFFAR1 | |
| SCHEMBL13092110 | 0.81 | CD274 (0.37) | KDM4ECD274ALDH1A1L3MBTL1PDCD1 | |
| SCHEMBL2913196 | 0.81 | FFAR1 (0.44) | KDM4ECD274ALDH1A1FFAR1 | |
| SCHEMBL12577697 | 0.80 | CD274 (0.44) | CD274ALDH1A1PDCD1 | |
| SCHEMBL13117692 | 0.80 | CD274 (0.40) | KDM4ECD274PDCD1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7968552-B2 | Oxadiazolidinedione compound | ASTELLAS PHARMA INC. (JP) | 2011-06-28 | — | — | US | disclosed |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| US-20090186909-A1 | Oxadiazolidinedione Compound | ASTELLAS PHARMA INC. (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-2011788-A1 | OXADIAZOLIDINEDIONE COMPOUND | Astellas Pharma Inc. (JP) | 2009-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186909-A1 | Oxadiazolidinedione Compound | GPR119, GPR39, GPR65 | KDM4E 2101/4885CD274 2600/4885ALDH1A1 3249/4885 |
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | KDM4E 2459/4885CD274 1333/4885ALDH1A1 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.